← Back to patent-cliff list
Oral Denatonium Acetate(Aardvark)
Tier C — Watch / tradeOral Denatonium Acetate(Aardvark)
Aardvark Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：TAS2Rs
Indications (approved)：体重增长, Obesity, Prader-Willi综合征, 摄食过度
Regional status
US
Phase II
2021-11-15
EU
Discontinued
2024-07-23
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Oral Denatonium Acetate(Aardvark)?
Approved indications include: 体重增长, Obesity, Prader-Willi综合征, 摄食过度.
When does the Oral Denatonium Acetate(Aardvark) patent expire?
No public expiry year is available for Oral Denatonium Acetate(Aardvark) yet; this page updates once verified.
How do I get a quote for Oral Denatonium Acetate(Aardvark) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21